Compare AstraZeneca plc (AZN) vs ProShares Ultra Bitcoin ETF (BITU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs ProShares Ultra Bitcoin ETF — how do they compare? AstraZeneca plc trades at $159.37 (market cap $250.84B), while ProShares Ultra Bitcoin ETF trades at $9.22. The key difference: AstraZeneca plc pays a 1.97% dividend while ProShares Ultra Bitcoin ETF pays none, and AstraZeneca plc is trading nearer its 52-week high, ProShares Ultra Bitcoin ETF nearer its low. Which is the better fit depends on your goals.
| AZN | BITU | |
|---|---|---|
Market Cap | $250.84B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $209.48 | $64.41 |
52-Week Low | $147.06 | $8.12 |
Enterprise Value | $278.12B | — |
Dividend Yield | 1.97% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $161.42, up 0.22% today, amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth to $58.74B in 2025 and net income of $10.23B, supported by a P/E of 24.16 and robust profitability margins. Recent news highlights potential talks with Bristol Myers Squibb, though a senior source denied ongoing discussions (Reuters, 2026-08-05).
The outlook is mixed: solid earnings beats and a 47.5% analyst buy rating support upside, but technical weakness and merger uncertainty pose near-term risks. Long-term growth hinges on execution amid competitive and regulatory pressures, with the stock offering value if merger rumors subside and fundamentals prevail.
BITU trades at $9.64, up 1.69% with neutral technical signals. The stock shows mixed momentum with bullish moving averages but neutral oscillators. Recent dividend payments of $0.01-$0.02 provide shareholder returns, though key financial ratios remain undisclosed in current filings.
The outlook remains cautious with technical indicators showing limited directional bias. Investment opportunity exists through dividend yield, but risks include volatility and lack of clear fundamental data. Analyst sentiment appears neutral with equal buy/sell recommendations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About ProShares Ultra Bitcoin ETF
BITU is a leveraged ETF that seeks to provide two times (2x) the daily performance of Bitcoin. It is designed for sophisticated investors looking for magnified exposure to Bitcoin’s daily price movements.
Read more on BITU →
